This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Third View: Discussing Xenon's Phase 2 results for Azetukalner in patients with focal onset seizures (FOS) presented at the American Epilepsy Society Annual Meeting 2024.

Ticker(s): XENE

Who's the expert?

Institution: Ochsner Health

  • Neurologist at Ochsner Health

Interview Goal
This call will focus on the treatment landscape and potential use of Azetukalner for patients with focal onset seizures.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.